Development of a transmission-blocking malaria vaccine: Progress, challenges, and the path forward

Vaccine

Volumn 32, Issue 43, 2014, Pages 5531-5539

  Nunes, Julia K ^a,e   Woods, Colleen ^a,b   Carter, Terrell ^a,f   Raphael, Theresa ^a   Morin, Merribeth J ^a   Diallo, Diadier ^c   Leboulleux, Didier ^d   Jain, Sanjay ^a,g   Loucq, Christian ^a,h   Kaslow, David C ^a,b   Birkett, Ashley J ^a  

^a PATH Malaria Vaccine Initiative   (United States)

^b PATH   (United States)

^c PATH Malaria Vaccine Initiative   (Senegal)

^d PATH Malaria Vaccine Initiative   (France)

^e Independent consultant   (India)

^f AMERICAN ACADEMY OF PEDIATRICS   (United States)

^g Novo Biosolutions Inc   (United States)

^h Stanford Institute for Innovation in Developing Economies   (United States)

Author keywords

Elimination; Eradication; Malaria vaccine; Transmission blocking

Indexed keywords

MALARIA VACCINE;

CLINICAL DEVELOPMENT PLAN; DISEASE TRANSMISSION; DRUG DESIGN; DRUG MANUFACTURE; HEALTH CARE POLICY; HUMAN; INFECTION PREVENTION; MALARIA; MEDICAL ETHICS; MOSQUITO; NONHUMAN; NOTE; PARASITE TRANSMISSION; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PROCESS DEVELOPMENT; ANIMAL; DISEASE CARRIER; MEDICAL RESEARCH; PARASITOLOGY; TRANSMISSION; TRENDS;

ANIMALS; BIOMEDICAL RESEARCH; CULICIDAE; HUMANS; INSECT VECTORS; MALARIA; MALARIA VACCINES;

EID: 84908555579     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.07.030     Document Type: Note

References (69)

1. Malaria Vaccine Funders Group Malaria Vaccine Technology Roadmap 2013, Available at: http://www.who.int/immunization/topics/malaria/vaccine_roadmap/TRM_update_nov13.pdf?ua=1.
2. Malaria Vaccine Funders Group Malaria Vaccine Technology Roadmap 2006, Available at: http://www.malariavaccine.org/files/Malaria_Vaccine_TRM_Final_000.pdf.
3. Roberts L., Enserink M. Malaria. Did they really say . . . eradication?. Science 2007, 318(5856):1544-1545. 10.1126/science.318.5856.1544.
4. Birkett A.J., Moorthy V.S., Loucq C., Chitnis C.E., Kaslow D.C. Malaria vaccine R&D in the decade of vaccines: breakthroughs, challenges and opportunities. Vaccine 2013, 31(Suppl. 2):B233-B243. 10.1016/j.vaccine.2013.02.040.
5. Alonso P.L., Brown G., Arevalo-Herrera M., Binka F., Chitnis C., Collins F., et al. A research agenda to underpin malaria eradication. PLoS Med 2011, 8(1):e1000406. 10.1371/journal.pmed.1000406.
6. The malERA Consultative Group on Integration Strategies A research agenda for malaria eradication: cross-cutting issues for eradication. PLoS Med 2011, 8(1):e1000404. 10.1371/journal.pmed.1000404.
7. The malERA Consultative Group on Health Systems and Operational Research A research agenda for malaria eradication: health systems and operational research. PLoS Med 2011, 8(1):e1000397. 10.1371/journal.pmed.1000397.
8. The malERA Consultative Group on Modeling A research agenda for malaria eradication: modeling. PLoS Med 2011, 8(1):e1000403. 10.1371/journal.pmed.1000403.
9. The malERA Consultative Group on Drugs A research agenda for malaria eradication: drugs. PLoS Med 2011, 8(1):e1000402. 10.1371/journal.pmed.1000402.
10. The malERA Consultative Group on Monitoring, Evaluation, and Surveillance A research agenda for malaria eradication: monitoring, evaluation, and surveillance. PLoS Med 2011, 8(1):e1000400. 10.1371/journal.pmed.1000400.
11. The malERA Consultative Group on Diagnoses and Diagnostics A research agenda for malaria eradication: diagnoses and diagnostics. PLoS Med 2011, 8(1):e1000396. 10.1371/journal.pmed.1000396.
12. A research agenda for malaria eradication: basic science and enabling technologies. PLoS Med 2011, 8(1):e1000399. 10.1371/journal.pmed.1000399.
13. The malERA Consultative Group on Vaccines A research agenda for malaria eradication: vaccines. PLoS Med 2011, 8(1):e1000398. 10.1371/journal.pmed.1000398.
14. The malERA Consultative Group on Vector Control A research agenda for malaria eradication: vector control. PLoS Med 2011, 8(1):e1000401. 10.1371/journal.pmed.1000401.
15. Pinder M., Moorthy V.S., Mendis K., Brown G.V. Measures of efficacy of preventive malaria interventions against malaria transmission 2010, Available at: http://www.who.int/immunization/research/meetings_workshops/MALVAC_2010_meeting_report.pdf.
16. PATH Malaria Vaccine Initiative. Workshop on malaria transmission-blocking vaccines June 2010 summary and outcomes. Available at: [accessed 04.04.14]. http://www.malariavaccine.org/files/TBV-workshop-summary-20140331.pdf.
17. UNDP, World Bank, World Health Organization Malaria transmission blocking vaccines: an ideal public good 2000.
18. Brooks A., Nunes J.K., Garnett A., Biellik R., Leboulleux D., Birkett A.J., et al. Aligning new interventions with developing country health systems: target product profiles, presentation, and clinical trial design. Glob Public Health 2012, 7(9):931-945. 10.1080/17441692.2012.699088.
19. US Food & Drug Administration Center for Drug Evaluation and Research Guidance for industry and review staff target product profile - a strategic development process tool 2007, Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm080593.pdf.
20. Blagborough A.M., Churcher T.S., Upton L.M., Ghani A.C., Gething P.W., Sinden R.E. Transmission-blocking interventions eliminate malaria from laboratory populations. Nat Commun 2013, 4:1812. 10.1038/ncomms2840.
21. Smith T.A., Chitnis N., Briët O.J.T., Tanner M. Uses of mosquito-stage transmission-blocking vaccines against Plasmodium falciparum. Trends Parasitol 2011, 27(5):190-196. 10.1016/j.pt.2010.12.011.
22. RTSS, Clinical Trials Partnership S., Agnandji S.T., Lell B., Fernandes J.F., Abossolo B.P., Methogo B.G., et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 2012, 367(24):2284-2295. 10.1056/NEJMoa1208394.
23. US Food and Drug Administration FDA guidance for industry general principles for the development of vaccines to protect against global infectious diseases 2011, Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/UCM282995.pdf.
24. Vannice K.S., Brown G.V., Akanmori B.D., Moorthy V.S. MALVAC 2012 scientific forum: accelerating development of second-generation malaria vaccines. Malar J 2012, 11:372. 10.1186/1475-2875-11-372.
25. Fleming T.R. Surrogate endpoints and FDA's accelerated approval process. Health Aff (Millwood) 2005, 24(1):67-78. 10.1377/hlthaff.24.1.67.
26. Penny M.A., Maire N., Studer A., Schapira A., Smith T.A. What should vaccine developers ask? Simulation of the effectiveness of malaria vaccines. PLoS ONE 2008, 3(9):e3193. 10.1371/journal.pone.0003193.
27. Miura K., Deng B., Tullo G., Diouf A., Moretz S.E., Locke E., et al. Qualification of standard membrane-feeding assay with Plasmodium falciparum malaria and potential improvements for future assays. PLoS ONE 2013, 8(3):e57909. 10.1371/journal.pone.0057909.
28. Bousema T., Dinglasan R.R., Morlais I., Gouagna L.C., van Warmerdam T., Awono-Ambene P.H., et al. Mosquito feeding assays to determine the infectiousness of naturally infected Plasmodium falciparum gametocyte carriers. PLoS ONE 2012, 7(8):e42821. 10.1371/journal.pone.0042821.
29. PATH Malaria Vaccine Initiative Portfolio 2014, Available at: http://www.malariavaccine.org/rd-portfolio.php [accessed 30.01.14].
30. Malaria Eradication Scientific Alliance. Available at: [accessed 30.01.14]. http://www.isglobal.org/-/malaria-eradication-scientific-alliance-mesa.
31. Tusting L.S., Bousema T., Smith D.L., Drakeley C. Measuring changes in Plasmodium falciparum transmission: precision, accuracy and costs of metrics. Adv Parasitol 2014, 151-208. 10.1016/B978-0-12-800099-1.00003-X.
32. London School of Hygiene and Tropical Medicine. Malaria research in epidemiology: assessment of the Infectious Reservoir of Malaria. Available at: [accessed 30.01.14]. http://malaria.lshtm.ac.uk/research/projects/malaria-research-epidemiology-14.
33. MESA Malaria Eradication Research Grants Malaria Eradication Science Alliance 2012, Available at: http://www.isglobal.org/documents/10179/64729/Project+summaries+MESA+grants+2012.pdf/1ca634be-11c0-41d4-b11e-4f572b7bea2a [accessed 30.01.14].
34. Mosha J.F., Sturrock H.J.W., Greenhouse B., Greenwood B., Sutherland C.J., Gadalla N., et al. Epidemiology of subpatent Plasmodium falciparum infection: implications for detection of hotspots with imperfect diagnostics. Malar J 2013, 12:221. 10.1186/1475-2875-12-221.
35. Okell L.C., Bousema T., Griffin J.T., Ouédraogo A.L., Ghani A.C., Drakeley C.J. Factors determining the occurrence of submicroscopic malaria infections and their relevance for control. Nat Commun 2012, 3:1237. 10.1038/ncomms2241.
36. Tiono A.B., Guelbeogo M.W., Sagnon N.F., Nébié I., Sirima S.B., Mukhopadhyay A., et al. Dynamics of malaria transmission and susceptibility to clinical malaria episodes following treatment of Plasmodium falciparum asymptomatic carriers: results of a cluster-randomized study of community-wide screening and treatment, and a parallel entomology. BMC Infect Dis 2013, 13:535. 10.1186/1471-2334-13-535.
37. Bousema T., Sutherland C.J., Churcher T.S., Mulder B., Gouagna L.C., Riley E.M., et al. Human immune responses that reduce the transmission of Plasmodium falciparum in African populations. Int J Parasitol 2011, 41(3-4):293-300. 10.1016/j.ijpara.2010.09.008.
38. Daniels R., Chang H.-H., Séne P.D. Genetic surveillance detects both clonal and epidemic transmission of malaria following enhanced intervention in Senegal. PLoS ONE 2013, 8(4):e60780. 10.1371/journal.pone.0060780.
39. US Centers for Disease Control Control and prevention of rubella: evaluation and management of suspected outbreaks, rubella in pregnant women, and surveillance for congenital rubella syndrome 2001, Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5012a1.htm.
40. Schleiss M.R. Cytomegalovirus vaccine development. Curr Top Microbiol Immunol 2008, 325:361-382. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2831992&tool=pmcentrez&rendertype=abstract [accessed 30.01.14].
41. Arvin A.M., Fast P., Myers M., Plotkin S., Rabinovich R. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis 2004, 39(2):233-239. 10.1086/421999.
42. World Health Organization. Country antimalarial drug policies: WHO South-East Asia Region. World Health Organisation. Available at: [accessed 30.01.14]. http://www.who.int/malaria/am_drug_policies_by_region_searo/en/index.html.
43. Baird J.K., Hoffman S.L. Primaquine therapy for malaria 2004, 39.
44. World Health Organization Updated WHO Policy Recommendation (October 2012): single dose primaquine as a gametocytocide in Plasmodium falciparum malaria. Geneva 2012, Available at: http://www.who.int/malaria/pq_updated_policy_recommendation_en_102012.pdf.
45. World Health Organization Country list: yellow fever vaccination requirements and recommendations; and malaria situation. International travel and health 2012 book 2012, World Health Organization, Geneva, Available at: http://www.who.int/ith/chapters/ith2012en_countrylist.pdf.
46. Bingham A., Gaspar F., Lancaster K., Conjera J., Collymore Y., Ba-Nguz A. Community perceptions of malaria and vaccines in two districts of Mozambique. Malar J 2012, 11(1):394. 10.1186/1475-2875-11-394.
47. Ojakaa D.I., Ofware P., Machira Y.W., et al. Community perceptions of malaria and vaccines in the South Coast and Busia regions of Kenya. Malar J 2011, 10:147. 10.1186/1475-2875-10-147.
48. Ojakaa D., Yamo E., Collymore Y., Ba-Nguz A., Bingham A. Perceptions of malaria and vaccines in Kenya. Hum Vaccin 2011, 7(10):1096-1099. 10.4161/hv.7.10.17496.
49. Maire N., Shillcutt S.D., Walker D.G., Tediosi F., Smith T.A. Cost-effectiveness of the introduction of a pre-erythrocytic malaria vaccine into the expanded program on immunization in sub-Saharan Africa: analysis of uncertainties using a stochastic individual-based simulation model of Plasmodium falciparum malaria. Value Health 2011, 14(8):1028-1038. 10.1016/j.jval.2011.06.004.
50. Smith T., Ross A., Maire N., Chitnis N., Studer A., Hardy D., et al. Ensemble modeling of the likely public health impact of the RTS,S malaria vaccine. PLoS Med 2012, 9(1.). 10.1371/journal.pmed.1001157.
51. World Health Organization Report on the WHO Quantitative Immunization and Vaccines Related Research (QUIVER): advisory committee meeting, 4-6 October 2011. Geneva 2012, Available at: http://whqlibdoc.who.int/hq/2012/who_ivb_12.03_eng.pdf.
52. Tediosi F., Maire N., Penny M., Studer A., Smith T.A. Simulation of the cost-effectiveness of malaria vaccines. Malar J 2009, 8:127. 10.1186/1475-2875-8-127.
53. PATH. Deadly epidemic gives rise to groundbreaking partnership. PATH Meningitis Vaccine Project. Available at: [accessed 30.01.14]. http://www.path.org/menafrivac/about-mvp.php.
54. Zipursky S., Djingarey M.H., Lodjo J.-C., Olodo L., Tiendrebeogo S., Ronveaux O. Benefits of using vaccines out of the cold chain: delivering meningitis A vaccine in a controlled temperature chain during the mass immunization campaign in Benin. Vaccine 2014, 32(13):1431-1435. 10.1016/j.vaccine.2014.01.038.
55. Jones R.M., Chichester J.A., Mett V., et al. A plant-produced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice. PLoS ONE 2013, 8(11):e79538. 10.1371/journal.pone.0079538.
56. Gregory J.A., Mayfield S.P. Developing inexpensive malaria vaccines from plants and algae. Appl Microbiol Biotechnol 2014, 10.1007/s00253-013-5477-6.
57. Wu Y., Przysiecki C., Flanagan E., et al. Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex. Proc Natl Acad Sci U S A 2006, 103(48):18243-18248. 10.1073/pnas.0608545103.
58. Kubler-Kielb J., Majadly F., Wu Y., et al. Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25. Proc Natl Acad Sci U S A 2007, 104(1):293-298. 10.1073/pnas.0609885104.
59. WHO. Malaria vaccine rainbow tables. Available at: [accessed 19.03.14]. http://www.who.int/immunization/research/development/Rainbow_tables/en/.
60. Cherif M.S., Shuaibu M.N., Kodama Y., et al. Nanoparticle formulation enhanced protective immunity provoked by PYGPI8p-transamidase related protein (PyTAM) DNA vaccine in Plasmodium yoelii malaria model. Vaccine 2014, 10.1016/j.vaccine.2014.01.005.
61. Bassat Q., Alonso P.L. Defying malaria: fathoming severe Plasmodium vivax disease. Nat Med 2011, 17(1):48-49. 10.1038/nm0111-48.
62. Baird J.K. Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clin Microbiol Rev 2013, 26(1):36-57. 10.1128/CMR.00074-12.
63. Lacerda M.V.G., Fragoso S.C.P., Alecrim M.G.C., et al. Postmortem characterization of patients with clinical diagnosis of Plasmodium vivax malaria: to what extent does this parasite kill?. Clin Infect Dis 2012, 55(8):e67-e74. 10.1093/cid/cis615.
64. Gething P.W., Elyazar I.R.F., Moyes C.L., et al. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis 2012, 6(9):e1814. 10.1371/journal.pntd.0001814.
65. Battle K.E., Gething P.W., Elyazar I.R.F., et al. The global public health significance of Plasmodium vivax. Adv Parasitol 2012, 80:1-111. 10.1016/B978-0-12-397900-1.00001-3.
66. Betuela I., Rosanas-Urgell A., Kiniboro B., et al. Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age. J Infect Dis 2012, 206(11):1771-1780. 10.1093/infdis/jis580.
67. Battle KE, van Boeckel TP, et al. A review of the geographical variation in Plasmodium vivax relapse rate. Philadelphia: American Society of Tropical Medicine and Hygiene. Available at: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=fae4c0aa-e07d-4fe8-b09b-4ffb158207b6&cKey=2a553dcf-b45e-4931-8b7d-4c48612a9b49&mKey={6BADBAB5-8298-4B1A-B5C2-0EEFA5120BB0}.
68. Bousema T., Drakeley C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev 2011, 24(2):377-410. 10.1128/CMR.00051-10.
69. Cohen J.M., Smith D.L., Cotter C., et al. Malaria resurgence: a systematic review and assessment of its causes. Malar J 2012, 11(1):122. 10.1186/1475-2875-11-122.